Gene Therapy for Age-related Macular Degeneration -A Pipeline Analysis Report
This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy molecules for age-related macular degeneration in the development and pre-clinical stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.
Technavio’s market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020.
Key questions answered in the report include
- What are the different stages of the pipeline molecules under investigation?
- What are the gene therapy molecules in the various development stages for age-related macular degeneration?
- What are the companies that are currently involved in the development of gene therapy molecules for age-related macular degeneration?
- What are the molecules discontinued from development?
- What are the major regulatory authorities approving drugs in various regions?
- Executive summary
- Scope of the report
- Research methodology
- Introduction
- Gene therapy for AMD: An insight
- Major regulatory authorities
- US
- Table Drug approval process by US FDA
- Europe
- Japan
- Australia
- China
- US
- Pipeline landscape
- Table Pipeline landscape
- Table Pipeline molecules by vendors
- Comparative analysis
- Table Pipeline molecules by numbers
- Table Pipeline molecules by percentage
- Discovery stage molecules
- Table Overview: Gene therapy for wAMD
- Table Overview: GS030
- Pre-clinical stage molecules
- Table Overview: ADVM-022/ADVM-032
- Table Overview: Gene therapy for dAMD
- Table Overview: A005
- Table Overview: A006
- Table Overview: RST-001
- Table Overview: CERE-120
- Table Overview: CERE-140
- Early-stage (Phase I) molecules
- Table Overview: OXB-201
- Table Clinical trials description of OXB-201
- Table Overview: RGX-314
- Table Clinical trials description of RGX-314
- Inactive and discontinued molecules
- Table Inactive and discontinued molecules by numbers
- Table Inactive and discontinued molecules
- Indication analysis
- Table Analysis by disease type
- Table Overview of indication
- Therapeutic assessment (therapy based)
- Table Assessment by monotherapy products by stagewise Monotherapy
- Therapeutic assessment (RoA based)
- Table Assessment by RoA
- Table Segmentation of pipeline by stage and RoA
- Therapeutic assessment by target
- Table Assessment by target
- Key companies
- Active companies: Category and parameters
- Table Vendor landscape
- Table Segmentation of companies
- Table Overview: Adverum
- Table Overview: AGTC
- Table Overview: Ceregene
- Table Overview: Gemini Therapeutics
- Table Overview: Gensight Biologics
- Table Overview: MeiraGTx
- Table Overview: Oxford BioMedica
- Table Overview: REGENXBIO
- Table Overview: RetroSense Therapeutics
- Active companies: Category and parameters
- Appendix
- List of abbreviations
- Explore Technavio
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook